- Advertise
- Contact Us
- Editorial Info
- Contribute
- Terms and Conditions
- Privacy Policy
- Do not sell my Personal Information
© 2023 MJH Life Sciences™ and Rheumatology Network. All rights reserved.
Rheumatoid Arthritis
The Rheumatology Network rheumatoid arthritis clinical focus page provides information on the latest rheumatoid arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for rheumatoid arthritis drugs.
Rheumatoid Arthritis Year in Review: 2022
December 29, 2022
Ayman Askari, MD, discusses the recent trends in rheumatoid arthritis, studies presented at the American College of Rheumatology (ACR) Convergence 2022, and the pressing issues that face rheumatologists moving into 2023.
Program Highlights Importance of Patient Perspective in Hispanic Patients with Rheumatoid Arthritis
December 14, 2022
“We realize, looking at the literature and also our clinical experience, that there are significant health disparities that are well documented in literature in Latinx and Hispanic rheumatoid arthritis patients, including perceptions of increased pain, fatigue, higher risk for depression, and a history of other self-help and self-management programs,” Adena Batterman, MSW, LCSW, explained.
Self-Evidence: When Treatment Based on the Experience of Others is not Enough
December 14, 2022
Self-evidence can help rheumatic autoimmune disease patients gain control of symptoms when the standard of care fails them.
Addition of TNFi, Triple Therapy Improved Vascular Inflammation in Patients with RA
December 07, 2022
Although previous studies have indicated differential effects on cardiovascular risk between immunomodulators, results showed similar reductions across both treatment groups.
Examining Drivers of Cardiovascular Risk with Tofacitinib, with Deepak Bhatt, MD, MPH
November 15, 2022
Deepak Bhatt, MD, MPH, discusses a posthoc analysis of the ORAL Surveillance trial examining drivers of increased cardiovascular risk observed in the phase 3b/4 trial in patients with rheumatoid arthritis.
Trial Finds 1-Week Methotrexate Hold As Effective for Vaccine Response as 2-Week Hold
November 14, 2022
A trial comparing a 1-week methotrexate hold following seasonal influenza vaccination against the standard 2-week hold among patients with rheumatoid arthritis using methotrexate suggests there were no significant differences in positive vaccine response with either approach.
Rheumatology Patients Report High Levels of Satisfaction With Adalimumab Biosimilar
November 13, 2022
ABP 501 is an adalimumab biosimilar that was recently approved the European Medicines Agency.
Daniel Hernandez, MD: Culturally Tailored Interventions for Hispanic Patients with RA
November 13, 2022
Investigators used interviews, performed in a patient’s preferred language and transcribed verbatim, to better uncover and understand what matters most to the Hispanic population.
Daniel Hernandez, MD: Determining the Educational Needs of Hispanic Patients with RA
November 13, 2022
“It’s very possible to reach the Hispanic community and to go above and beyond what is currently being done, which is very little in terms of supporting them and giving them the tools that they need to create to have a better quality of life."
Glucocorticoid Use Results in BMD Loss for Women with Rheumatic Disease
November 11, 2022
Anti-osteoporotic treatment resulted in increased BMD to a greater extent in patients treated with less than 5 mg per day of prednisone.